dryey
syndrom
de
multifactori
diseas
ocular
surfac
character
rapid
evapor
insuffici
product
tear
de
lead
inflamm
ocular
surfac
damag
cornea
conjunctiva
therebi
impact
visual
function
affect
qualiti
life
de
preval
increas
age
sever
worsen
patholog
condit
syndrom
induc
disrupt
ocular
surfac
epithelium
chronic
graftversushost
diseas
gvhd
regular
use
artifici
tear
antiinflammatori
drop
punctal
plug
provid
releas
howev
temporari
often
induc
ocular
side
effect
serum
eye
drop
sed
made
human
blood
recent
emerg
altern
appar
moreeffici
method
convent
treatment
improv
ocular
surfac
health
tear
film
stabil
subject
comfort
refractori
de
therapeut
benefit
sed
probabl
multifactori
explain
composit
share
similar
tear
includ
antimicrobi
compon
variou
plateletderiv
growth
factor
fibronectin
vitamin
albumin
major
serum
compon
may
also
contribut
amelior
ocular
surfac
damag
sed
current
often
prepar
autolog
blood
donat
within
hospit
blood
establish
howev
prepar
autolog
serum
requir
particular
attent
repeat
blood
sampl
patient
constraint
thu
potenti
imposs
clinic
situat
patient
condit
will
donat
blood
autolog
sourc
unavail
allogen
serum
made
serum
blood
transfus
donor
next
obviou
option
therapeut
term
appear
equal
effici
autolog
sed
allogen
serum
prepar
blood
establish
product
set
compli
good
manufactur
practic
gmp
principl
ensur
product
standard
qualiti
substanti
advantag
allogen
sed
offtheshelf
avail
main
potenti
safeti
concern
associ
allogen
sed
base
histor
experi
transfus
blood
product
risk
infect
bloodborn
pathogen
particularli
virus
concern
clinician
patient
although
data
avail
indic
extent
possibl
infecti
risk
associ
use
allogen
topic
sed
viral
safeti
strategi
therapeut
blood
product
involv
care
donor
screen
blood
donat
test
human
immunodefici
viru
hiv
hepat
b
c
virus
howev
inform
transfus
intraven
blood
compon
indic
measur
prevent
residu
risk
infecti
windowphas
donat
screen
test
reactiv
donor
actual
infecti
addit
blood
suppli
regularli
expos
emerg
virus
dengu
viru
chikungunya
viru
ebola
viru
middl
east
respiratori
syndrom
coronaviru
zika
viru
transmit
blood
product
current
higher
margin
safeti
blood
compon
wide
rang
virus
achiev
implement
dedic
viru
pathogen
inactiv
treatment
treatment
base
photochem
pathogen
viru
inactiv
recent
develop
plasma
platelet
blood
compon
serum
proprietari
natur
restrict
evalu
new
product
like
sed
contrast
solventdeterg
sd
treatment
develop
late
public
domain
sd
treatment
alreadi
appli
wide
rang
biopharmaceut
prepar
plasma
product
highli
effici
lipidenvelop
virus
report
first
time
applic
sd
treatment
viral
inactiv
sed
also
compar
safeti
efficaci
sdtreat
untreat
rabbit
sed
de
rabbit
model
determin
whether
sd
treatment
realist
safe
option
viral
inactiv
allogen
sed
experiment
protocol
approv
institut
anim
care
use
committe
taipei
medic
univers
iacuc
approv
male
new
zealand
rabbit
purchas
anim
health
research
institut
council
agricultur
execut
yuan
taiwan
weigh
kg
sign
ocular
inflammatori
gross
abnorm
use
anim
hous
standard
cage
lightcontrol
room
given
food
water
ad
libitum
examin
surgic
procedur
rabbit
perform
gener
anesthesia
administ
via
intramuscular
inject
mixtur
zoletil
virbac
anial
health
nice
franc
rompun
solut
bayer
kyonggido
korea
studi
design
summar
fig
explain
blood
collect
five
rabbit
cardiac
punctur
blood
rabbit
approxim
ml
allow
clot
h
gener
serum
centrifug
xg
min
supernat
serum
recov
pool
ml
total
divid
two
fraction
aliquot
ml
filter
filter
remov
bacteria
insolubl
materi
serum
dispens
eppendorf
tube
mltube
frozen
remain
ml
serum
subject
sd
treatment
polyvinyl
chlorid
bag
use
vv
trinbutyl
phosphat
tnbp
merck
darmstadt
germani
vv
triton
sigma
st
loui
mo
usa
h
constant
gentl
stir
mixtur
extract
clarifi
ad
vv
soybean
oil
sigma
vigor
shake
mild
shake
min
decant
min
previou
research
clarifi
bottom
protein
layer
recov
upper
oil
layer
discard
residu
sd
agent
remov
treat
protein
phase
hydrophob
interact
chromatograph
adsorpt
ratio
ml
per
g
sorbent
octadecyl
poros
water
guyancourt
franc
h
mixtur
centrifug
xg
supernat
sdserum
recov
sterilefilt
filter
frozen
total
protein
quantifi
bradford
assay
sodium
dodecylsulf
polyacrylamid
gel
electrophoresi
sdspage
nonreduc
reduc
condit
perform
use
gradient
gel
reagent
electrophoret
system
invitrogen
carlsbad
ca
usa
prestain
protein
molecular
weight
standard
novex
sharp
invitrogen
transform
growth
factor
tgf
content
determin
enzymelink
immunosorb
assay
elisa
rabbit
shanghai
yehua
biolog
technolog
shanghai
china
epiderm
growth
factor
egf
rabbit
egf
sandwich
elisa
kit
mybiosourcecom
san
diego
ca
usa
rabbit
hous
rel
humid
altern
lightdark
cycl
de
induc
describ
previou
studi
slight
modif
briefli
eye
topic
treat
eye
drop
contain
benzalkonium
chlorid
bac
sigmaaldrich
st
loui
mo
usa
tripledaili
drip
week
clinic
observ
schirmer
test
fluorescein
stain
perform
central
corneal
thick
cct
determin
de
induc
bac
treatment
rabbit
follow
bac
treatment
rabbit
randomli
divid
five
group
four
group
treat
twice
daili
week
use
variou
formul
phosphatebuff
salin
pb
serum
sdserum
bac
addit
week
neg
control
fifth
group
treatment
serv
control
week
treatment
de
condit
rabbit
examin
describ
aqueou
tear
secret
measur
schirmer
strip
madhu
instrument
new
delhi
india
briefli
rabbit
underw
gener
anesthesia
immobil
intramuscular
inject
ml
mixtur
zoletil
rompun
solut
oper
conduct
test
defin
time
point
standard
control
environ
topic
administr
alcon
puur
belgium
lower
eyelid
slightli
pull
paper
strip
schirmer
test
place
palpebr
conjunctiv
vesica
locat
near
junction
middl
outer
third
lower
lid
min
length
wet
paper
strip
read
data
express
millimet
eye
test
twice
interv
averag
length
paper
wet
calcul
corneal
fl
stain
perform
de
induct
therapeut
effect
also
evalu
week
treatment
fl
paper
strip
haagstreit
ag
konizbern
switzerland
smear
directli
cornea
let
dye
drop
onto
conjunctiv
sac
ocular
surfac
examin
grade
slitlamp
microscop
cobaltblu
filter
topcon
medic
system
oakland
nj
usa
anim
euthan
overdos
anesthet
ketamin
zylazin
mgkg
cornea
collect
one
cornea
divid
two
equal
part
one
part
fix
formaldehyd
buffer
solut
least
h
histolog
observ
one
without
fixat
frozen
protein
extract
describ
next
section
fix
specimen
embed
paraffin
section
cornea
stain
hematoxylin
eosin
h
e
sigma
histolog
examin
termin
deoxynucleotidyl
transferas
deoxyuridin
triphosph
nick
end
label
tunel
stain
perform
examin
apoptosi
corneal
epithelium
use
apobrduihctm
situ
dna
fragment
assay
kit
follow
supplier
recommend
biovis
milpita
ca
usa
thaw
cornea
weigh
separ
chop
small
piec
liquid
nitrogen
ad
immers
tissu
solidif
ground
powder
step
repeat
three
time
tissu
extract
solut
contain
tper
tissu
protein
extract
reagent
halttm
proteas
phosphatas
inhibitor
cocktail
thermo
fisher
scientif
rockford
il
usa
ad
tissu
ratio
ml
per
g
cornea
tissueextract
mixtur
kept
min
mill
room
temperatur
anoth
min
protocol
repeat
five
time
tissueextract
mixtur
centrifug
xg
min
remov
tissu
debri
tissu
extract
collect
analyz
coomassi
protein
assay
thermo
fisher
scientif
normal
protein
content
sampl
subsequ
cytokin
analysi
elisa
total
protein
load
plate
elisa
rabbit
tumor
necrosi
factor
tnf
determin
use
kit
r
system
minneapoli
mn
usa
rabbit
interleukin
il
respect
determin
use
kit
mybiosourc
san
diego
ca
usa
follow
supplier
instruct
valu
present
mean
standard
deviat
sd
standard
error
mean
sem
statist
differ
group
assess
use
oneway
analysi
varianc
anova
post
hoc
test
tukey
test
use
spss
spss
inc
chicago
il
usa
probabl
p
valu
less
consid
statist
signific
protein
content
sed
sdsed
mgml
respect
sdspage
reveal
substanti
differ
protein
composit
regardless
molecular
mass
expect
promin
band
correspond
albumin
fig
level
ngml
sed
sdsed
respect
wherea
egf
undetect
pgml
prepar
timelin
de
induct
treatment
follow
first
rabbit
treat
bac
three
time
daili
week
establish
de
next
rabbit
establish
de
treat
sed
sdsed
twice
daili
week
tear
product
examin
eye
drop
treatment
period
tear
secret
rapidli
decreas
eye
treat
bac
mimic
de
pb
compar
normal
eye
group
significantli
differ
control
group
normal
eye
p
compar
de
group
tear
product
significantli
differ
p
group
treat
sed
sdsed
still
lower
normal
group
fig
treatment
period
ocular
surfac
experiment
eye
stain
fl
examin
slitlamp
microscop
obviou
stain
observ
eye
normal
anim
fig
contrast
darkgreen
stain
observ
center
cornea
eye
treat
bac
fig
opaqu
zone
center
cornea
observ
eye
treat
pb
fig
stain
observ
cornea
eye
treat
either
sed
sdsed
fig
examin
light
microscop
show
normal
cornea
control
three
five
layer
epitheli
cell
dens
collagen
fibril
stroma
fig
corneal
section
bactreat
group
show
thinner
corneal
epithelium
two
three
layer
loos
collagen
fibril
stroma
fig
corneal
section
pb
group
thinner
corneal
epithelia
loos
stroma
fig
contrast
rabbit
treat
sed
sdsed
normal
corneal
epithelia
normal
number
layer
thick
fig
tunel
common
method
detect
dna
fragment
result
apoptot
signal
cascad
assay
cell
suffer
sever
dna
damag
stain
dark
brown
normal
eye
control
show
nearli
tunelposit
cell
fig
contrast
eye
treat
bac
de
show
larg
number
apoptot
cell
corneal
basal
epithelium
stroma
fig
wherea
treat
pb
also
show
apoptot
cell
corneal
epithelium
stroma
fig
eye
treat
sed
sdsed
show
fewer
tunelposit
cell
fig
inflamm
cornea
assess
elisa
measur
express
inflammatori
cytokin
respons
variou
treatment
fig
higher
level
detect
bac
de
treat
group
expect
sinc
model
mimic
inflammatori
condit
associ
de
p
concentr
significantli
reduc
sed
sdsedtreat
group
compar
de
group
p
concentr
inflam
cornea
treat
sed
sdsed
higher
normal
control
group
lower
destreat
one
evidenc
partial
relief
inflammatori
condit
concentr
group
much
higher
normal
cornea
therefor
accord
result
use
sed
sdsed
topic
deliveri
treat
de
rabbit
could
select
inhibit
inflammatori
cytokin
eye
de
frequent
disord
preval
elderli
patient
syndrom
chronic
gvhd
de
symptom
includ
pain
irrit
itch
burn
gritti
seriou
advers
impact
daili
life
activ
addit
de
associ
inflamm
ocular
surfac
artifici
tear
antiinflammatori
drop
punctal
plug
convent
treatment
provid
partial
benefit
addit
side
effect
eye
drop
made
human
serum
emerg
altern
probabl
superior
treatment
de
sed
prepar
autolog
sourc
far
use
frequent
standard
prepar
procedur
use
close
cascad
filtrat
system
develop
howev
trend
toward
use
allogen
offtheshelf
sed
prepar
control
gmp
condit
blood
establish
still
legitim
concern
associ
use
allogen
sed
risk
viral
contamin
although
donor
screen
donat
test
provid
high
viral
safeti
margin
risk
complet
elimin
even
develop
economi
access
effici
nucleic
acid
viral
test
procedur
due
residu
windowphas
donat
hiv
hepat
b
viru
hepat
c
viru
addit
world
popul
due
increas
travel
migrat
global
warm
regularli
expos
new
emerg
virus
virus
collect
asymptomat
blood
donor
untest
could
potenti
transmit
sed
recipi
although
extent
risk
viral
infect
still
current
unknown
shown
instanc
respiratori
syncyti
viru
use
eye
entri
pathway
replic
robustli
eventu
migrat
lung
thu
optim
viral
safeti
allogen
sed
requir
implement
addit
safeti
measur
dedic
pathogen
inactiv
treatment
implement
manufactur
among
pathogeninactiv
procedur
theoret
applic
sed
sd
select
sed
effici
lipidenvelop
virus
repres
major
threat
safeti
bloodderiv
product
therefor
evalu
sd
treatment
possibl
tool
enhanc
safeti
sed
elect
treat
sed
combin
tnbp
triton
condit
appli
plasma
cryoprecipit
known
inactiv
within
minut
log
hiv
porcin
pseudorabi
bovin
viral
diarrhea
viru
hepat
c
viru
dengu
viru
sd
treatment
affect
virus
disrupt
lipid
envelop
remov
also
inactiv
bacteria
well
parasit
white
blood
cell
sd
treatment
alter
plasma
protein
function
content
includ
albumin
shown
contribut
apoptosi
suppress
ocular
epithelium
cell
dryey
model
addit
quit
importantli
sd
treatment
shown
alter
antimicrobi
antiinflammatori
activ
plasma
compon
show
procedur
base
soybean
oil
extract
hydrophob
interact
chromatographi
effici
remov
sd
agent
therebi
avoid
toxic
therefor
treatment
capabl
provid
high
safeti
margin
lipidenvelop
virus
without
impair
key
function
featur
sed
howev
quantit
loss
protein
associ
sd
treatment
step
particular
oil
extract
adsorpt
compar
efficaci
sed
whether
sd
treat
reliev
de
use
preclin
rabbit
model
de
induc
topic
administr
bac
preserv
ophthalm
drug
worsen
preexist
dryey
condit
bac
alter
cornea
conjunctiva
lead
physiolog
chang
mimick
de
symptom
human
larg
ocular
surfac
rabbit
eye
permit
adequ
monitor
tear
product
moreeffici
histolog
biochem
analys
compar
mice
anim
model
inspir
previous
publish
method
modifi
expos
eye
bac
three
time
daili
week
follow
treatment
bac
sed
result
stabl
de
state
spontan
recov
discontinu
bac
result
demonstr
pathogen
inactiv
impair
efficaci
sed
reliev
de
symptom
rabbit
model
base
follow
relev
evalu
criteria
restor
tear
product
fl
stain
observ
histolog
examin
quantif
inflammatori
marker
conclus
data
support
possibl
perform
pathogen
inactiv
treatment
sed
use
sd
treatment
data
confirm
use
human
sed
open
perspect
develop
standard
pool
allogen
sed
